# Eilean Therapeutics

Source: https://onco.cc/companies/eilean-therapeutics/  
OnCo record `eilean-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eilean Therapeutics designs tablet medicines for blood cancers that are built to keep working when the cancer mutates; its first drug in people targets the faulty JAK2 protein behind polycythaemia vera and myelofibrosis.

## Summary

Eilean Therapeutics Inc. is a privately held small-molecule oncology company established in 2022, according to the company, focused on pan-variant therapies for haematological malignancies. Its pipeline lists lomonitinib (FLT3/IRAK4, acute myeloid leukaemia), lonitoclax (BCL2), balomenib (menin) and ZE74-0282, a selective inhibitor of mutated JAK2 V617F for polycythaemia vera and myelofibrosis, together with preclinical programmes. Its only registry study sponsored under this name, through the Australian subsidiary Eilean Therapeutics AU Pty Ltd, is a phase 1 safety study of ZE74-0282 in healthy volunteers (NCT07527221), posted on ClinicalTrials.gov in April 2026; it has no registered cancer trial under this sponsor name.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Eilean Therapeutics Inc.; Eilean Therapeutics AU Pty Ltd
- HQ: Dover, DE
- Type: biotech
- Website: https://www.eileanther.com/

## Notes

- Founding year, pipeline and contact address read on the company website on 29 October 2026. The only address given is 8 The Green, Dover, Delaware, which is a registered-office address and may not be where the company works. Registry study read on 29 October 2026. The registry has no cancer-patient trial under this sponsor; other Eilean programmes may be registered under partners' names, which was not checked. No financing found.

## Sources

- Official website: https://www.eileanther.com/
- Pipeline: https://www.eileanther.com/pipeline
- ClinicalTrials.gov: phase 1 study of ZE74-0282 in healthy volunteers (NCT07527221): https://clinicaltrials.gov/study/NCT07527221

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Polycythaemia vera (PV)](https://onco.cc/cancers/polycythaemia-vera/), [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FLT3](https://onco.cc/targets/flt3/), [JAK2](https://onco.cc/targets/jak2/), [Menin](https://onco.cc/targets/menin/)

---
JSON: https://onco.cc/api/v1/entities/eilean-therapeutics.json